Written by Brian Beck + Legally reviewed by William Ettenger, Esq
Last Updated: August 30th, 2026
⚡ Quick Answer
What is the Dexcom lawsuit? Patients and families are suing Dexcom, Inc. over its G6 and G7 continuous glucose monitors (CGMs), alleging the devices provided inaccurate glucose readings and failed to deliver critical low- and high-glucose alerts, leading to severe hypoglycemia, hyperglycemia, diabetic ketoacidosis, seizures, coma, and death. The claims follow multiple Class I FDA recalls in 2025 affecting over 600,000 devices, a March 2025 FDA warning letter citing unauthorized sensor modifications, and more than 500,000 adverse event reports tied to the G6 alone. Five related federal class actions are currently pending before a single judge in the Southern District of California, with motions to consolidate the cases and appoint interim class counsel still awaiting a ruling. Individual injury and wrongful death lawsuits continue to be filed separately across the country. No global settlement has been reached.
Who Qualifies for a Dexcom Lawsuit
Eligibility focuses on people who used a Dexcom G6 or G7 continuous glucose monitor and suffered a documented medical event tied to a device failure — an inaccurate reading, a missed or delayed alert, or a complete malfunction.
Qualifying Criteria:
What Is Dexcom CGM?
Dexcom's continuous glucose monitoring (CGM) systems are wearable medical devices that let people with diabetes track blood glucose in real time without frequent fingerstick tests. The system pairs a small sensor inserted under the skin with a wireless transmitter and either a dedicated receiver or a smartphone app that displays readings and issues alerts.
Dexcom G6: FDA-approved in 2018, marketed as providing accurate readings every five minutes with alerts for dangerously low or high blood sugar, and widely integrated with insulin pumps for automated dosing decisions.
Dexcom G7: Dexcom's next-generation CGM, with a smaller form factor, faster warm-up time, and a 10-day wear period, marketed as an accuracy and usability upgrade over the G6.
Patients and doctors relied on these readings to make life-or-death insulin dosing decisions. When the devices misread glucose levels or failed to alert users to danger, the FDA says the consequences were sometimes catastrophic — including seizures, diabetic comas, and death. In March 2025, the FDA revealed that Dexcom made unauthorized changes to critical sensor components, and its own internal studies showed the modified sensors had "significantly greater variability" than the versions the FDA had approved. Similar patterns of alleged corporate knowledge show up in other defective medical device cases.
Dexcom Recalls & FDA Actions
Dexcom's CGM systems have been the subject of repeated FDA recalls and regulatory actions:
January 2025 — G6 Touchscreen Receiver Recall
Software design flaws on G6 receivers running a .NET operating system caused delayed or missed glucose alerts. Dexcom issued software updates to resolve the issue.
March 2025 — FDA Warning Letter
The FDA cited Dexcom for "adulteration" of G6 and G7 devices tied to quality system failures, including unauthorized design changes to critical sensor components made without FDA approval. Dexcom's own clinical studies reportedly showed the modified sensors had "significantly greater variability," and the FDA stated the resulting inaccuracies created "higher risks for users who rely on the sensors to dose insulin."
June 2025 — Class I Recall (Most Serious)
Over 600,000 G6, G7, ONE, and ONE+ receivers were recalled worldwide after defective foam or assembly errors caused receiver speakers to lose contact with circuit boards, preventing audible alerts for dangerous glucose levels. The FDA logged 56 injuries tied to this recall, including seizures, loss of consciousness, and vomiting.
September 2025 — Second Class I Recall
An additional Class I recall covered further sensor alert failures and system malfunctions, again classified by the FDA as carrying serious risk of injury or death.
October 2025 — G6 Android App Recall
Dexcom recalled 333 G6 CGM systems after finding that the Android mobile app could crash unexpectedly, cutting users off from glucose data or alerts for dangerously high or low blood sugar. The issue was resolved with an app update.
Device Complications & Injuries Recognized in Active Claims
The strongest cases involve serious, documented medical events traceable to a specific device failure — not just general dissatisfaction with accuracy.
The FDA has received over 500,000 adverse event reports tied to the Dexcom G6 alone, with 13 deaths documented. More than 600,000 receivers were recalled in 2025 for speaker malfunctions that prevented critical alerts.
Dexcom Lawsuit Settlement Ranges & Key Factors
No global settlement has been reached. Individual injury and wrongful death cases are evaluated on their own facts; based on comparable medical device litigation, attorneys point to rough ranges while stressing these are not guarantees:
- 💀
Wrongful death: potentially $2–5 million or more, where device failure directly caused death
- 🧠
Permanent injury: roughly $500,000–$2 million for brain damage, organ damage, or lasting disability from severe glucose episodes
- 🏥
Hospitalization: roughly $100,000–$500,000 for emergency treatment, ICU stays, or repeat hospitalizations
- ⚠️
Moderate injury: roughly $50,000–$150,000 for documented device failures causing seizures or serious complications without permanent injury
- 💵
Class action refunds: separate from personal injury claims, the pending federal class actions seek refunds for consumers who purchased allegedly defective G6 and G7 devices
Disclaimer: These are predictions based on comparable medical device litigation, not a settlement program specific to Dexcom. Actual outcomes depend on case-specific facts.
Class Action Status & Court Proceedings
Dexcom's litigation is currently split into two separate tracks, and it's important not to confuse them:
Federal Class Actions — Southern District of California
Five related federal class actions have been assigned to a single judge in the Southern District of California. Plaintiffs filed motions on December 30, 2025 and January 5, 2026 to consolidate the cases, appoint interim class counsel, and set a briefing schedule on competing counsel-appointment motions. Those motions are still pending. The court has stayed Dexcom's deadline to respond to any of the complaints until a consolidated complaint is filed. This is not a federal MDL — no petition to the Judicial Panel on Multidistrict Litigation has consolidated these cases nationally; it is a district-level coordination of related cases.
State Class Action — Los Angeles County
A putative class action pending in Los Angeles County Superior Court has been stayed in favor of the federal proceedings. The parties must file a joint status report on the federal class actions no later than August 19, 2026.
Individual Personal Injury & Wrongful Death Claims
Separate from the class actions above, individual product liability and wrongful death lawsuits continue to be filed in state and federal courts nationwide by patients and families alleging specific injuries or deaths. These cases proceed independently and are not resolved by any refund-focused class settlement.
Deadlines for Filing a Dexcom Lawsuit
Deadlines for medical device product liability claims typically range from 2 to 4 years, and most states apply a "discovery rule" that starts the clock when you knew or should have known the device caused your injury — not necessarily the date you started using it. The 2025 recalls and FDA warning letter may serve as key discovery dates. Wrongful death claims typically must be filed within 1 to 3 years of the date of death, and these deadlines are strictly enforced.
Do not assume it is too late. Evidence gathering, medical record review, and expert retention take time — speak with an attorney as soon as possible to confirm your specific deadline.
Dexcom Lawsuit Updates — 2026
Last updated August 2026. We update this section as new filings, recalls, and court rulings occur.
-
August 2026 LatestJoint Status Report Deadline Approaches: Per court order, the parties in the Southern District of California class actions must file a joint status report on the state of the federal proceedings no later than August 19, 2026. Dexcom's deadline to respond to any complaint remains stayed pending a consolidated complaint.
-
Early 2026Discovery Motions Filed; No MDL or Class Certification Yet: Plaintiffs' attorneys filed motions seeking internal company documents on product testing, quality control, and complaint handling. As of mid-2026, no class has been formally certified and no bellwether trials have been scheduled — legal observers expect more clarity on the litigation's direction in the second half of 2026.
-
January 5, 2026Second Round of Consolidation Motions Filed: Plaintiffs filed further motions to consolidate the five related Southern District of California class actions and to resolve competing bids for interim class counsel.
-
December 30, 2025Plaintiffs Move to Consolidate Federal Class Actions: Plaintiffs in the five related Southern District of California cases filed motions to consolidate the actions and appoint interim class counsel, kicking off the procedural fight over how the federal litigation will be organized.
-
January 2026FDA Flags Software Issue in Dexcom App: The FDA flagged a serious software issue in Dexcom's glucose monitoring app, raising concerns about device reliability beyond the hardware failures already at issue in the recalls.
-
December 2025Dexcom Announces End of G6 Production: Dexcom said it would cease G6 production by July 1, 2026 (a date that has since passed), recommending users move to the G7 or G7 15 Day — timing that coincided with mounting recalls and litigation.
-
November 2025Securities Class Action Filed: A separate securities class action was filed on behalf of Dexcom investors who purchased stock between July 26, 2024 and September 17, 2025, alleging the company made false statements about device safety and quality.
-
October 2025G6 Android App Recall & New Class Action: Dexcom recalled 333 G6 systems after finding its Android app could crash and cut off glucose data or alerts. Separately, a class action was filed demanding a jury trial over claims that Dexcom's G7 marketing was false, misleading, and deceptive, placing users at risk of severe hypoglycemia, hyperglycemia, seizure, coma, or death.
-
September 2025Wisner Baum Files Class Action; Second Class I Recall: Wisner Baum filed a class action in the U.S. District Court for the Southern District of California on behalf of G6 and G7 purchasers, seeking refunds and damages for false advertising. The FDA separately issued a second Class I recall for additional sensor failures and alert malfunctions.
-
July 2025FDA Announces Class I Recall of 600,000+ Receivers: The FDA publicly announced the Class I recall affecting over 600,000 G6, G7, ONE, and ONE+ receivers worldwide due to speaker malfunctions preventing critical glucose alerts, following Dexcom's June notification to affected customers.
-
June 2025Dexcom Issues Urgent Medical Device Correction: Dexcom warned that certain G6 and G7 receivers failed to provide audio alerts for dangerous glucose levels. Over 100 complaints had been filed by this point, including 56 reports of severe adverse events such as seizures and loss of consciousness.
-
March 2025FDA Warning Letter Issued: The FDA cited Dexcom for "adulteration" of G6 and G7 devices due to unauthorized modifications of critical sensor components made without FDA approval, revealing Dexcom's own studies had shown the modified sensors carried "significantly greater variability."
-
January 2025G6 Touchscreen Receiver Recall: A recall was issued for G6 touchscreen receivers running a .NET operating system, after software design flaws caused delayed or missed glucose alerts. Software updates resolved the issue.
-
April 2024Tennessee Wrongful Death Lawsuit Filed: A Tennessee widow filed a wrongful death lawsuit against Dexcom and Tandem Diabetes Care after her husband died while using a Dexcom monitor, naming both device manufacturers as defendants.
Harmed By a Dexcom G6 or G7 Failure? Find Out for Free
Attorneys are reviewing Dexcom cases nationwide. You pay nothing unless compensation is recovered.
Start My Free Case ReviewHow the Dexcom Lawsuit Process Works
Attorneys handle Dexcom injury cases on contingency — you pay nothing unless compensation is recovered.
- Free confidential case review — Discuss your device use, malfunction, and resulting injury with an attorney at no cost.
- Preserve your device and records — If you still have the receiver, transmitter, or sensor, keep it. Screenshots of error messages or inaccurate readings help establish what happened.
- Case review and evidence gathering — Your attorney collects medical records, device serial numbers, and determines whether your device was part of a recalled batch.
- Expert evaluation — Medical experts and device engineers assess causation between the device failure and your injury.
- Filing the lawsuit — Your attorney files an individual product liability or wrongful death claim in the appropriate state or federal court.
- Discovery — Both sides exchange evidence, including Dexcom's internal communications, design documents, and FDA submissions.
- Settlement or trial — Most medical device cases resolve through settlement once discovery reveals what the company knew. Similar strategies apply in cases like Bard PowerPort and Cartiva toe implant litigation.
Frequently Asked Questions
Is there a Dexcom MDL?
Not a formal one. Five related federal class actions have been assigned to a single judge in the Southern District of California, but no petition has consolidated these into a nationwide MDL through the Judicial Panel on Multidistrict Litigation. Individual personal injury and wrongful death cases are filed separately and are not part of this coordination.
Can I sue Dexcom if their device caused my injury?
Yes. You may be able to file an individual lawsuit if a G6 or G7 device gave an inaccurate reading, failed to alert you to a dangerous glucose level, or otherwise malfunctioned in a way that caused a serious injury or death. These claims are separate from the pending refund-focused class actions.
How much are Dexcom lawsuit settlements worth?
No global settlement exists. Based on comparable device litigation, wrongful death cases may be valued higher (potentially $2–5 million+), permanent injury cases in the $500,000–$2 million range, and hospitalization cases roughly $100,000–$500,000 — though actual outcomes depend entirely on case-specific facts.
What is the status of the Dexcom class action?
As of August 2026, motions to consolidate five related federal class actions in the Southern District of California and appoint interim class counsel remain pending. Dexcom's response deadlines are stayed, and a related Los Angeles County state class action has been stayed in favor of the federal case. A joint status report is due August 19, 2026.
How long do I have to file a Dexcom lawsuit?
Deadlines vary by state, typically 2 to 4 years for device claims, starting when you discovered (or should have discovered) the injury. Wrongful death claims are typically 1 to 3 years from the date of death. Speak with an attorney promptly to confirm your specific deadline.
Was my Dexcom device part of a recall?
Visit dexcom.com/checkreceiver and enter your receiver's serial number. Recalls in 2025 covered G6, G7, ONE, and ONE+ receivers (speaker defects), G6 touchscreen receivers (software), and the G6 Android app (crashes). Even if your device wasn't part of a recalled batch, you may still have a claim if a failure caused injury.
Sources & FDA Documents
- U.S. Food and Drug Administration (FDA) — regulatory oversight, warning letters, and recall information
- FDA MAUDE Database — adverse event reports for Dexcom devices
- FDA Medical Device Recalls — official recall notices and classifications
- Dexcom, Inc. Form 10-Q — SEC filing detailing the status of federal and state class action proceedings
- Dexcom, Inc. — manufacturer information and device correction notices
